Literature DB >> 9238164

[Receptors for factors of the VEGF (Vascular Endothelial Growth Family)].

E Fournier1, D Birnbaum, J P Borg.   

Abstract

Growth factors of the VEGF (vascular endothelial growth factor) family comprises 4 well characterized members that play a crucial role in the biology of blood vessels. They interact with 3 high affinity tyrosine kinase receptors (FLT1/VEGFR1, FLK1/KDR/VEGFR2, FLT4/VEGFR3). VEGF/VEGFR interactions have essential functions in blood vessel formation during development, specific phases of adult life, and in some pathological processes with neo-vascularization such as tumor growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9238164

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  5 in total

1.  Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature.

Authors:  J Grunstein; J J Masbad; R Hickey; F Giordano; R S Johnson
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

2.  Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology.

Authors:  Cleber A Trujillo; Arthur A Nery; Janaína M Alves; Antonio H Martins; Henning Ulrich
Journal:  Clin Ophthalmol       Date:  2007-12

3.  Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells.

Authors:  M Akagi; M Kawaguchi; W Liu; M F McCarty; A Takeda; F Fan; O Stoeltzing; A A Parikh; Y D Jung; C D Bucana; P F Mansfield; D J Hicklin; L M Ellis
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

4.  RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth and induces apoptosis in mouse breast cancer in vitro and in vivo.

Authors:  Yong-Chao Liu; Wen-Hui Ma; Yin-Lin Ge; Mei-Lan Xue; Zheng Zhang; Jin-Yu Zhang; Lin Hou; Run-Hong Mu
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

Review 5.  Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.

Authors:  Md Emranul Karim; Kyi Kyi Tha; Iekhsan Othman; Mohammad Borhan Uddin; Ezharul Hoque Chowdhury
Journal:  Pharmaceutics       Date:  2018-05-26       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.